GILEAD SCIENCES, INC. is 203.7x more valuable than Cullinan Therapeutics, Inc. by market capitalization ($150.83 B vs $740.57 M). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CGEM | GILD |
|---|---|---|
| Market cap | $740.57 M | $150.83 B |
| US-listed rank | #2664 | #99 |
| Revenue (latest FY) | $0.00 | $29.44B |
| Net income (latest FY) | -$219.88M | $8.51B |
| Net margin | - | 28.9% |
| P/E (trailing FY) | - | 17.7 |
| SEC filings | 435 | 981 |
GILEAD SCIENCES, INC. is 203.7x more valuable than Cullinan Therapeutics, Inc. by market capitalization ($150.83 B vs $740.57 M).
Full pages: Cullinan Therapeutics, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.